Reactive Lymphadenopathy During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: Two Case Reports

Background: Tyrosine kinase inhibitors (TKIs) are the cornerstone of chronic myeloid leukemia (CML) therapy. Although generally well tolerated, they may have adverse effects that warrant attention and are rarely documented such as lymphadenopathy mimicking disease progression and prompting unnecessa...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Abdulelah Alotaibi, Abdulrahman Alshehri, Shimaa Elkholy, Noha Eisa
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Kasr Al-Ainy Center of Clinical Oncology and Nuclear Medicine 2026-06-01
Edice:	Research in Oncology
Témata:	chronic myeloid leukemia dasatinib lymphadenopathy nilotinib tyrosine kinase inhibitors
On-line přístup:	https://resoncol.journals.ekb.eg/article_516219_191d250c402e65ff9610ce9fb7abf734.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!